HIV‐infection during treatment of a chronic hepatitis B virus infection: implications for PrEP?

HIV‐infection during treatment of a chronic hepatitis B virus infection: implications for PrEP?

The protective effect of oral tenofovir disoproxil fumarate (TDF) with or without emtricitabine (FTC) as pre‐exposure prophylaxis (PrEP) against HIV differed significantly among clinical studies and poor PrEP‐adherence was closely associated with PrEP‐failure. Despite HIV‐infections during PrEP‐expo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the International AIDS Society 2012-11, Vol.15 (S4), p.1-1
Hauptverfasser: Storim, J, Jochum, C, Timm, J, Schadendorf, D, Esser, S
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
AIDS
Antiretroviral agents
Antiretroviral drugs
Deoxyribonucleic acid
Disease transmission
DNA
Drug resistance
Hepatitis
Hepatitis B
HIV
Human immunodeficiency virus
Infections
Medical tests
Mutation
Prophylaxis
Sexually transmitted diseases
STD
Syphilis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The protective effect of oral tenofovir disoproxil fumarate (TDF) with or without emtricitabine (FTC) as pre‐exposure prophylaxis (PrEP) against HIV differed significantly among clinical studies and poor PrEP‐adherence was closely associated with PrEP‐failure. Despite HIV‐infections during PrEP‐exposure the development of resistance mutations against PrEP was rarely observed so far. As PrEP is an emerging tool against HIV transmission, it is important to identify risk‐factors for PrEP‐failure and the induction of PrEP‐associated resistance mutations against antiretroviral drugs. We here present the case of a 25‐year old MSM who was successfully treated with TDF due to a chronic hepatitis B virus (HBV) infection (HBV‐DNA always
ISSN:1758-2652
1758-2652
DOI:10.7448/IAS.15.6.18169